Literature DB >> 36057079

Clinical Features and Neuroimaging Findings of Neuropil Antibody-Positive Idiopathic Sporadic Ataxia of Unknown Etiology.

Akira Takekoshi1, Akio Kimura1, Nobuaki Yoshikura1, Isamu Yamakawa2, Makoto Urushitani2, Katsuya Nakamura3, Kunihiro Yoshida4, Takayoshi Shimohata5.   

Abstract

Idiopathic sporadic ataxia (ISA) is the clinical term for nonfamilial ataxia with adult-onset and a slowly progressive course. However, immune-mediated cerebellar ataxia cannot be completely excluded from ISA. The current study investigated the neuropil antibodies against cell-surface antigens and clarified the clinical features and neuroimaging findings of patients with these antibodies. Using tissue-based immunofluorescence assays (TBAs), we examined antibodies against the cerebellum in serum samples from 67 patients who met the ISA diagnostic criteria, including 30 patients with multiple system atrophy with predominant cerebellar features (MSA-C) and 20 patients with hereditary ataxia (HA), and 18 healthy control subjects. According to the TBA results, we divided subjects into three groups: subjects positive for neuropil antibodies, subjects positive for intracellular antibodies only, and subjects negative for antibodies. We compared clinical features and neuroimaging findings in ISA patients among these three groups. The prevalence of neuropil antibodies in ISA (17.9%) was significantly higher than that in MSA-C (3.3%), HA (0%), or healthy subjects (0%). The neuropil antibody-positive ISA patients showed pure cerebellar ataxia more frequently than the other ISA patients. Two neuropil antibody-positive patients showed significant improvement of cerebellar ataxia after immunotherapy. We detected neuropil antibodies in 17.9% of ISA patients. Characteristic clinical features of neuropil antibody-positive ISA patients were pure cerebellar ataxia. Some cases of neuropil antibody-positive ISA responded to immunotherapy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Autoantibody; Cerebellar ataxia; Idiopathic sporadic ataxia; Immunotherapy; Tissue-based immunofluorescence assay

Year:  2022        PMID: 36057079     DOI: 10.1007/s12311-022-01468-3

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.648


  35 in total

1.  Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.

Authors:  P Sillevis Smitt; A Kinoshita; B De Leeuw; W Moll; M Coesmans; D Jaarsma; S Henzen-Logmans; C Vecht; C De Zeeuw; N Sekiyama; S Nakanishi; R Shigemoto
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

2.  Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration.

Authors:  Esther de Graaff; Peter Maat; Esther Hulsenboom; Robert van den Berg; Martin van den Bent; Jeroen Demmers; Pieternella J Lugtenburg; Casper C Hoogenraad; Peter Sillevis Smitt
Journal:  Ann Neurol       Date:  2012-03-23       Impact factor: 10.422

3.  CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia.

Authors:  W F Abdo; B P C van de Warrenburg; M Munneke; W J A van Geel; B R Bloem; H P H Kremer; M M Verbeek
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

4.  A comparative study of cardiac dysautonomia in autosomal dominant spinocerebellar ataxias and idiopathic sporadic ataxias.

Authors:  M Netravathi; T N Sathyaprabha; K Jayalaxmi; P Datta; M Nirmala; P K Pal
Journal:  Acta Neurol Scand       Date:  2009-09       Impact factor: 3.209

5.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

6.  Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration.

Authors:  H M Furneaux; M K Rosenblum; J Dalmau; E Wong; P Woodruff; F Graus; J B Posner
Journal:  N Engl J Med       Date:  1990-06-28       Impact factor: 91.245

7.  Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia.

Authors:  Masato Kanazawa; Mari Tada; Osamu Onodera; Hitoshi Takahashi; Masatoyo Nishizawa; Takayoshi Shimohata
Journal:  Parkinsonism Relat Disord       Date:  2013-08-03       Impact factor: 4.891

8.  Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics.

Authors:  Marios Hadjivassiliou; Richard Grünewald; Basil Sharrack; David Sanders; Alan Lobo; Clare Williamson; Nicola Woodroofe; Nicholas Wood; Aelwyn Davies-Jones
Journal:  Brain       Date:  2003-03       Impact factor: 13.501

9.  Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate.

Authors:  M Hadjivassiliou; R A Grunewald; P D Shanmugarajah; P G Sarrigiannis; P Zis; V Skarlatou; N Hoggard
Journal:  Cerebellum       Date:  2020-10       Impact factor: 3.847

10.  Clinical and Imaging Features of Multiple System Atrophy: Challenges for an Early and Clinically Definitive Diagnosis.

Authors:  Hirohisa Watanabe; Yuichi Riku; Kazuhiro Hara; Kazuya Kawabata; Tomohiko Nakamura; Mizuki Ito; Masaaki Hirayama; Mari Yoshida; Masahisa Katsuno; Gen Sobue
Journal:  J Mov Disord       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.